CompletedNot applicableNCT03167697
Evaluating the Efficacy of PKU Synergy in Patients Expressing Phenylketonuria or Hyperphenylalaninemia
Studying Disorder of phenylalanine metabolism
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Nutricia UK Ltd
- Principal Investigator
- Rebecca Stratton, PhDNutricia UK
- Intervention
- Synergy(dietary_supplement)
- Enrollment
- 14 enrolled
- Eligibility
- 16-100 years · All sexes
- Timeline
- 2017 – 2018
Study locations (6)
- Queen Elizabeth Hospital, Birmingham, United Kingdom
- Royal Hospital for Sick Children, Edinburgh, United Kingdom
- Queen Elizabeth University Hospital, Glasgow, United Kingdom
- Guys & St Thomas' Hospital, London, United Kingdom
- Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom
- Southampton General Hospital, Southampton, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03167697 on ClinicalTrials.govOther trials for Disorder of phenylalanine metabolism
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07220265Impact of Phenylalanine Elevations on Brain and Cognition in Adult PKU CarriersUniversity of Missouri-Columbia
- RECRUITINGPHASE2NCT06637514A Phase 2 Study of JNT-517 in Adolescent Participants With PhenylketonuriaOtsuka Pharmaceutical Development & Commercialization, Inc.
- RECRUITINGPHASE3NCT06628128A Study to Evaluate the Long-Term Safety and Efficacy of JNT-517 in Participants With PhenylketonuriaOtsuka Pharmaceutical Development & Commercialization, Inc.
- RECRUITINGNANCT05579548A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq® (Pegvaliase) During Pregnancy and BreastfeedingBioMarin Pharmaceutical
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04480567AAV Gene Therapy Study for Subjects with PKUBioMarin Pharmaceutical